Mouaz Al-Mallah, MD
Cardiovascular Disease · Detroit, MINPI 1255446217
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by GE HealthCare at 57.0% of the total. 2025 is the largest year on record at $20,601, more than ten times the $512 reported in 2019. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $321.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$24K
- Jubilant Draximage Inc.$8K
- Jubilant Draximage, Inc.$3K
- Siemens Medical Solutions USA, Inc.$2K
- Pfizer$2K
- Heartflow, Inc.$1K
- plus $2K from 17 others
Across 25 payments — averaging $17,297 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$358K
- Cleerly, Inc.$60K
- Siemens Medical Solutions USA, Inc.$15K
What the payments were for
- Consulting fees$18,70044%
- Speaking & faculty fees$16,20838%
- Travel & lodging$2,8187%
- Food & beverage$4,96812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 35 | $24,349 |
| Jubilant Draximage Inc. | 3 | $8,170 |
| Jubilant Draximage, Inc. | 1 | $2,750 |
| Siemens Medical Solutions USA, Inc. | 18 | $2,129 |
| Pfizer | 13 | $1,856 |
| Heartflow, Inc. | 12 | $1,410 |
| Philips North America LLC | 6 | $754 |
| Amgen | 19 | $340 |
| Cleerly, Inc. | 2 | $249 |
| Abbott | 6 | $228 |
| Bridgebio Pharma, Inc. | 1 | $76 |
| Medtronic | 3 | $66 |
| Boston Scientific | 1 | $50 |
| Astellas Pharma US Inc | 2 | $48 |
| Lantheus Medical Imaging, Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Lemaitre Vascular, Inc. | 1 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Novartis | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flyrcado$12,600
- RUBY-FILL$10,900
- VYNDAQEL$1,500
- NAEOTOM Alpha$1,447
- FFRct$1,139
- (6479) Spectral CT 7500$599
- Biograph Vision 600 (8 Ring/64 CT)$312
- Cleerly Labs$249
- Cleerly Ischemia$113
- TRICLIP$113
- VYNDAMAX$101
How this compares
$42,693 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $43,786 |
| FarxigaDapagliflozin Propanediol | 20 | $13,157 |
| Repatha SureclickEvolocumab | 15 | $11,433 |
| XareltoRivaroxaban | 11 | $9,067 |
| JardianceEmpagliflozin | 12 | $6,897 |
| BrilintaTicagrelor | 11 | $4,888 |
| Ezetimibe | 70 | $2,907 |
| Rosuvastatin Calcium | 125 | $2,039 |
| Atorvastatin Calcium | 99 | $1,249 |
| Nifedipine ErNifedipine | 31 | $779 |
| Losartan Potassium | 59 | $710 |
| Metoprolol Succinate | 54 | $696 |
| Metoprolol Tartrate | 44 | $661 |
| Hydralazine Hcl | 39 | $603 |
| Carvedilol | 37 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,856 | $43,78634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Detroit
- Pedro Villablanca SpinettoDetroit$620K
- Wayne WeaverDetroit$340K
- Brian OneillDetroit$250K
- Karthikeyan AnanthasubramaniamDetroit$112K
- Gerald KoenigDetroit$96K
- David LanfearDetroit$82K
- Celeste WilliamsDetroit$70K
- Mahir ElderDetroit$68K
- Cori RussellDetroit$67K
- Pedro Engel GonzalezDetroit$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.